Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch

Executive Summary

When Lilly's Effient (prasugrel) finally cleared FDA July 10, the first thing everyone noticed is the "black box" warning of a potential increased risk of bleeding associated with the antithrombotic drug

You may also be interested in...



The Biology Police: The Plavix Investigation and Pharmacogenomics

The discovery of a genetic marker for Plavix resistance is one of the milestones in the regulatory application of pharmacogenomics. Is it also a crime drama?

Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?

Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly

Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?

Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel